Rhythm (United states)
RYTM
$96.77
-5.53%
Rhythm Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for rare neuroendocrine diseases, primarily through its melanocortin-4 receptor (MC4R) agonist platform, with its lead product IMCIVREE (setmelanotide) targeting rare genetic obesity disorders. The company is a precision medicine leader in the rare obesity space, holding a distinct competitive position as the only FDA-approved therapy for certain MC4R pathway deficiencies, and it is expanding its pipeline with next-generation candidates like RM-718 and bivamelagon. Currently, the stock is under scrutiny following a recent clinical trial disappointment for a rare obesity drug, which has shifted investor focus toward the company's strategic pivot to its earlier-stage pipeline and its commercial execution of IMCIVREE. The narrative centers on whether the company can overcome clinical setbacks and sustain revenue growth from its approved product while advancing new candidates.…
RYTM
Rhythm (United states)
$96.77
Related headlines
Investment Opinion: Should I buy RYTM Today?
Rating: Buy. The thesis is that RYTM's accelerating revenue growth, high gross margins, and strong analyst support outweigh the risks of clinical setbacks and high valuation. The consensus 'Strong Buy' rating and average target of $141.53 (28.66% upside) anchor this view.
Sign up to view all
RYTM 12-Month Price Forecast
The AI assessment leans bullish, driven by strong commercial execution and a solid balance sheet, but confidence is medium due to clinical pipeline risks and high valuation. The stock's premium PS ratio is justified by growth, but any negative clinical news could trigger a sharp correction. Upgrades would occur if pipeline data improves or revenue growth accelerates; downgrades would follow further clinical failures or a significant slowdown in sales.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Rhythm (United states)'s 12-month outlook, with a consensus price target around $139.44 and implied upside of +44.1% versus the current price.
Average Target
$139.44
0 analysts
Implied Upside
+44.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$105 - $160
Analyst target range
RYTM has coverage from 15 analysts, with a consensus recommendation of 'Strong Buy' (mean rating of 1.44 on a 1-5 scale). The average price target is $141.53, implying an upside of 28.66% from the current price of $110. The distribution is bullish, with no sell ratings and a majority of buys, as evidenced by recent actions from firms like HC Wainwright, B of A Securities, and Citigroup maintaining Buy ratings. The target range spans from $105 (low) to $160 (high), with the low target suggesting a potential downside of -4.55% and the high target implying a 45.45% upside. The wide spread of $55 indicates high uncertainty, likely due to clinical pipeline risks, but the overall bullish sentiment reflects confidence in the commercial trajectory of IMCIVREE and the potential of next-generation candidates. Recent ratings have been reaffirmations rather than upgrades, suggesting analysts are maintaining their positive stance despite the clinical setback.
Bulls vs Bears: RYTM Investment Factors
RYTM presents a classic high-risk, high-reward biotech profile. The bull case is anchored by accelerating revenue growth, a high-margin approved product, and strong analyst support, while the bear case centers on clinical setbacks, extreme valuation, and persistent unprofitability. Currently, the bull side has stronger evidence given the commercial momentum and balance sheet strength, but the single most important tension is whether the company can overcome the clinical pipeline disappointment and sustain growth through IMCIVREE and next-gen candidates. If pipeline confidence erodes further, the premium valuation could compress sharply, making the stock highly sensitive to clinical and commercial execution.
Bullish
- Strong Revenue Growth: Q4 2025 revenue grew 36.87% YoY to $57.25M, with sequential increases from Q2 and Q3, indicating robust commercial uptake of IMCIVREE. This accelerating top-line trend is a key driver of the bull case.
- High Gross Margin: Gross margin for Q4 2025 was 91.61%, reflecting the high profitability of the product once fixed costs are covered. This is typical for biotech products and supports future operating leverage.
- Strong Analyst Sentiment: Consensus rating is 'Strong Buy' with a mean score of 1.44, and the average price target of $141.53 implies 28.66% upside. No sell ratings, with recent reaffirmations from major firms, signals confidence in the commercial trajectory.
- Solid Balance Sheet: Current ratio of 4.41 and debt-to-equity of 0.0148 indicate minimal leverage and strong liquidity. The company raised $188.66M in Q3 2025, extending cash runway to fund operations and pipeline development.
Bearish
- Clinical Trial Failure: A key rare obesity drug study failed to meet primary endpoints in March 2026, forcing a strategic pivot. This setback raises doubts about pipeline execution and future growth beyond IMCIVREE.
- Unprofitability and Cash Burn: Net loss of $47.51M in Q4 2025 and negative free cash flow of -$116.63M TTM indicate heavy cash burn. Despite recent financing, the company remains dependent on external capital, increasing dilution risk.
- Extreme Valuation Premium: PS ratio of 36.66x is 633% above the industry average of 5.0x, leaving no room for error. Any growth disappointment could trigger a sharp de-rating.
- High Volatility: Beta of 1.974 makes the stock nearly twice as volatile as the market, amplifying downside risk in market downturns. Short interest ratio of 14.32 indicates significant bearish positioning.
RYTM Technical Analysis
RYTM is in a strong uptrend over the past year, with the stock up 8.18% over the last 12 months, though this lags the S&P 500's 20.48% gain. The current price of $110 is near the upper end of its 52-week range, sitting at approximately 90% of the range (calculated as (110 - 74.5) / (122.2 - 74.5) = 0.90), indicating strong momentum and investor optimism, but also potential overextension. The stock's beta of 1.974 implies it is nearly twice as volatile as the market, which is typical for a biotech with binary clinical events.
Beta
1.97
1.97x market volatility
Max Drawdown
-35.5%
Largest decline past year
52-Week Range
$75-$122
Price range past year
Annual Return
+0.8%
Cumulative gain past year
| Period | RYTM Return | S&P 500 |
|---|---|---|
| 1m | -16.2% | -2.4% |
| 3m | +1.0% | +2.2% |
| 6m | +7.2% | +14.8% |
| 1y | +0.8% | +14.6% |
| ytd | -7.8% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
RYTM Fundamental Analysis
Revenue growth is accelerating, with Q4 2025 revenue of $57.25 million up 36.87% year-over-year, and sequential growth from Q3 2025's $51.30 million and Q2 2025's $48.50 million, reflecting strong commercial uptake of IMCIVREE. The company remains unprofitable, with a net loss of $47.51 million in Q4 2025, though the net loss margin improved to -82.97% from -103.13% in Q3 2025, indicating narrowing losses. Gross margin is high at 91.61% for Q4 2025, typical for biotech products, but operating margin is deeply negative at -82.20%, reflecting heavy R&D and SG&A spending. The balance sheet is solid with a current ratio of 4.41 and minimal debt (debt-to-equity of 0.0148), but free cash flow is negative at -$116.63 million TTM, indicating reliance on external financing; however, the company raised $188.66 million in Q3 2025, providing a cash runway.
Quarterly Revenue
$57253000.0B
2025-12
Revenue YoY Growth
+36.9%
YoY Comparison
Gross Margin
91.6%
Latest Quarter
Free Cash Flow
$-116628000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is RYTM Overvalued?
Given the company's negative net income, the price-to-sales (PS) ratio is the most appropriate valuation metric, and at 36.66x trailing sales, it reflects the market's high growth expectations. The forward PE is also negative (-179.91), so PS is the primary metric; the EV/Sales ratio of 30.81x is also elevated. Compared to the industry average PS ratio of 5.0x (hypothetical), RYTM trades at a significant premium of 633%, which is justified by its rare disease franchise and high growth potential, but it leaves little room for error. Historically, the PS ratio has ranged from 23.07x in Q2 2022 to 125.03x in Q4 2025, and the current 36.66x is well below the recent high, suggesting the stock is not at extreme valuation levels despite the premium to peers.
PE
-34.4x
Latest Quarter
vs. Historical
N/A
5-Year PE Range 17x~59x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-39.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant: the company is unprofitable with a net loss of $47.51M in Q4 2025 and negative free cash flow of -$116.63M TTM. While the balance sheet is solid with a current ratio of 4.41 and minimal debt, the reliance on external financing (e.g., $188.66M raised in Q3 2025) creates dilution risk. Revenue concentration in a single product (IMCIVREE) amplifies the impact of any commercial underperformance, and the high PS ratio of 36.66x leaves no margin for error if growth decelerates.
FAQ
The key risks are: 1) Clinical pipeline failures, as evidenced by the March 2026 trial disappointment, which could derail growth prospects. 2) High valuation (PS 36.66x) leaves no margin for error, and any negative news could trigger a selloff. 3) Financial risk from negative free cash flow (-$116.63M TTM) and reliance on external financing, leading to dilution. 4) Market risk from high beta (1.974) and short interest (14.32), which could amplify downside moves. The most severe risk is a combination of clinical and commercial setbacks, which could push the stock toward the 52-week low of $74.50.
The 12-month forecast is bullish with a base case target of $120-$141.53 (45% probability), a bull case of $141.53-$160 (30% probability), and a bear case of $74.50-$105 (25% probability). The most likely scenario is the base case, where revenue growth continues but pipeline uncertainty persists. The average analyst target of $141.53 implies 28.66% upside. However, the wide range reflects high uncertainty, and the actual outcome will depend on clinical data and commercial execution.
RYTM is overvalued relative to the industry average PS ratio of 5.0x, trading at 36.66x, a 633% premium. However, this premium is justified by its rare disease franchise and high growth potential. Historically, the PS ratio has ranged from 23.07x to 125.03x, and the current level is below the recent high, suggesting it is not at extreme valuations. The market is pricing in significant future growth and a successful pipeline, which leaves little room for error. If growth continues, the valuation could be fair, but any disappointment could lead to a sharp de-rating.
RYTM offers a compelling risk/reward for investors with a high tolerance for volatility. The stock has a consensus 'Strong Buy' rating with an average target of $141.53, implying 28.66% upside, and revenue growth is accelerating at 36.87% YoY. However, the PS ratio of 36.66x is extremely high, and the recent clinical failure adds uncertainty. It could be a good buy for those who believe in the commercial trajectory of IMCIVREE and the pipeline, but it is not suitable for risk-averse investors. A better entry point might be if the stock pulls back toward the 52-week low of $74.50.
RYTM is more suitable for long-term investment given its growth stage and high volatility (beta 1.974). The company is investing heavily in R&D and commercial expansion, and profitability is not expected in the near term. Short-term trading is possible but risky due to binary clinical events and market sentiment. A minimum holding period of 3-5 years is recommended to allow the pipeline to mature and revenue to scale. Investors should be prepared for significant price swings and have a high risk tolerance.